Antiplatelet Therapy in Patients with Arteriosclerosis obliterans (ASO)
Yoshiaki Okano(National Cerebral and Cardiovascular Center), Yutaka HARANOH(National Cerebral and Cardiovascular Center), Y Nishioeda(Institute for Atherosclerosis Research), Kazuo Mogami(Chiba University), Masako Waki(Shizuoka City Hospital), Hideki KOH(Institute for Atherosclerosis Research), Masaaki Suzuki(Institute for Atherosclerosis Research), Yoshiya KOMATSU(National Cerebral and Cardiovascular Center), Tatsuo Matsuyama(Institute for Atherosclerosis Research), Motoo TSUSIMA(National Cerebral and Cardiovascular Center)
Cited by 0
Related Papers
Plasma Brain Natriuretic Peptide as a Prognostic Indicator in Patients With Primary Pulmonary Hypertension
|Circulation|2000|880
Plasma Brain Natriuretic Peptide Levels Increase in Proportion to the Extent of Right Ventricular Dysfunction in Pulmonary Hypertension
|Journal of the American College of Cardiology|1998|578
Differences in skeletal muscle and bone mineral mass between black and white females and their relevance to estimates of body composition
|American Journal of Clinical Nutrition|1992|285
Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy
|European Heart Journal|2019|235
Relative expansion of extracellular fluid in obese vs. nonobese women
|American Journal of Physiology-Endocrinology and Metabolism|1991|204